US/UK/Canada

Share

Links

Quotes

This order is of strategic importance for Attana, since we are now involved at an early stage in designing R&D projects for a major drug development project. The order shows a market acceptance for our technology and capability to characterize interactions with cells, tissues, viruses etc it also provides a value of our application knowledge and the advises we can provide.
International Sales Manager Thomas Ljungberg
Pick a time period -
Tags ( Active)

Attana increases focus on customer-centric operations

Attana implements organizational changes to ensure more customer-centric operations and an increased focus on sales within all business functions.Attana has during the year continued to optimize the organization and deepen strategic collaborations with the goal of focusing the company's resources on key customers. Technical development continues to be performed in close collaboration with select customers and partners under the management of Attana personnel. The organizational changes are summarized below: Life Science - The company's key customers have been allocated a dedicated Attana

Attana now offers self sampling for expanded diagnostic testing capabilities with an updated CE IVD-marking

Attana now enables self sampling through an updated CE IVD-marking for capillary blood samples using Capitainer[®]qDBS cards (quantitative dried blood spot), enabling laboratories improved opportunities to perform immune profiling and monitoring of vaccine efficacy in broad patient populations.As presented together with Capitainer in February 2022, the goal of Attana Diagnostics is to offer broader and more patient-centric blood sampling solutions for the Attana AVA[TM] system. Since then, Attana has validated its AVA[TM] SARS-CoV-2 IgG Immunoassay kit for capillary blood samples, both qDBS

Attana inks microsampling collaboration with Capitainer for improved diagnostic sampling

Combining Attana’s advanced biosensor system with Capitainer’s DBS home sampling makes immune profiling and vaccine efficacy monitoring possible in broad patient populations.Swedish bio- and healthtech companies Attana AB and Capitainer AB have signed an agreement with the goal of offering broader and more patient-centric blood sampling solutions for the Attana AVA[TM] system starting with COVID-19 immune profiling. Since November 2021, Attana has been performing comparative studies of finger stick capillary blood samples simultaneously collected by both test tubes and Capitainer®qDBS

Attana and Triolab sign distribution agreement for all Attana products on the Swedish market

Attana can today announce that the company has signed a distribution agreement with Triolab AB for the marketing and sales of all Attana products on the Swedish market.In June, Attana and Triolab signed a memorandum of understanding (MOU) for the distribution of the newly launched Attana Diagnostics products. Since then, the parties have performed joint sales and marketing activities towards select customers in Sweden. Today, the companies have signed a distribution agreement for the Swedish market which includes all products within both Attana business units: Diagnostics and Life

New study with Medical University of Innsbruck validates Attana Virus Analytics (AVA™) for SARS-CoV-2 diagnostics

In a new study conducted by Attana and Medical University of Innsbruck, a number of individuals have been tested for COVID-19 with both AVA[TM] and EUROIMMUN’s ELISA-based technology. The results show that Attana’s technology accurately measures the concentration of SARS-CoV-2 antibodies with at least the precision of current FDA-approved technology.Description of results The Medical University of Innsbruck delivered samples from 6 different individuals in Austria, on which Attana performed analyses using the AVA platform. All samples have also undergone tests for SARS-CoV-2 spike-

Attana has launched a redesigned website as an initial step in a new communications and marketing plan

Attana has launched a redesigned website at www.attana.com with a new graphic profile along with revised content. The website will be continuously updated to ensure accessibility to relevant information as well as improvements in usability and functionality, as needed.“As we embark on the next chapter in Attana’s history we want our website to set the tone for all of our upcoming communication- and marketing efforts. We are pleased to now provide our customers, partners, and investors with a better understanding of the many benefits our products and services offer,’ comments Teodor Aastrup,

Attana CEO Teodor Aastrup presents the company’s most recent progress at Erik Pensers Company Day (“Bolagsdag”) September 24[th]

Follow the presentation here . It will be a 20-minute presentation between 11.35 and 11.55 covering the following topics: · Introduction to Attana · Recruitment of Niklas Carlsson as COO and VP · Progress of communication and marketing efforts · Ongoing work with the current product offering: Contract Research and Instrument Sales · Update on Attana Diagnostic projects (AVA): · Results of Attana COVID-19 diagnostics study · Results of Attana Tetanus diagnostics study · Results of Attana diagnostics

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe